What is it?
What memantine is
1Memantine is a synthetic adamantane-derived prescription medicine and NMDA receptor antagonist. It appears in nootropic retail contexts, but the regulated evidence base is clinical and condition-specific rather than supplement-style cognitive enhancement evidence.
Names, aliases and forms
Mechanisms of action
NMDA receptor antagonism
14Memantine blocks NMDA receptor activity in a moderate-affinity, uncompetitive manner. That mechanism is relevant to its clinical rationale, but it should not be converted into a broad claim that memantine enhances healthy cognition.
Potential effects and evidence map
Human evidence is strongest in regulated clinical use for moderate-to-severe Alzheimer-type dementia, where systematic reviews find small, population-specific benefits. That evidence should not be generalized to healthy cognitive enhancement: direct healthy-volunteer evidence is sparse and not supportive of broad memory, attention, or mood benefits.
Has condition-specific human evidence for small cognition-related benefits in moderate-to-severe Alzheimer-type dementia populations; this does not prove healthy memory enhancement.
Healthy focus or attention enhancement is unproven from reliable human evidence.
NMDA-receptor pharmacology provides a clinical rationale in specific disease contexts, but it is not proof of general neuroprotection or healthy brain support.
Typical dosages and timing
U.S. immediate-release labeling starts at 5 mg once daily and titrates in 5 mg/day increments at minimum one-week intervals to 20 mg/day in the approved clinical context. This is label context, not guidance for unsupervised nootropic use.
For severe renal impairment, defined in the U.S. label as A kidney-function estimate based on creatinine levels in urine and blood.Source 5-29 mL/min, labeling specifies this lower target in the approved clinical context. This is prescribing context, not consumer dosing advice.
Onset, duration and tolerance
This is the label absorption marker for peak plasma concentration, not a reliable onset estimate for cognitive effects.
This supports the compact half-life field and explains why changes may persist beyond a single day.
EMA scientific discussion reports steady-state plasma levels were attained by day 11. This is exposure timing, not a proven nootropic onset.
NHS patient information says memantine can take up to 3 months to begin working, with person-to-person variation. This is dementia-treatment response timing, not acute nootropic onset.
UK SmPC language says maintenance treatment can continue while therapeutic benefit remains favourable and memantine is tolerated, with reassessment preferably within three months after starting and regularly thereafter. This is treatment-duration guidance, not single-dose effect duration.
The source audit found clinical response timing (up to 3 months in NHS patient information), pharmacokinetic timing supported by label, FDA regulator review, EMA scientific discussion, and human PK literature (The time it takes to reach the highest measured blood concentration after a dose.Source 3-7 hours, half-life 60-80 hours, steady state around day 11), and treatment-duration reassessment guidance. It did not find a reliable acute nootropic onset or single-dose effect-duration value, so the compact onsetText, durationText, and timingText fields remain blank.
Safety, side effects and risk profile
U.S. and EU sources checked on 2026-06-28 describe memantine as a prescription medicine, not a dietary supplement.
Other NMDA antagonists and urine-alkalinizing drugs are explicit label cautions.
Memantine is substantially renally cleared and label dosing changes in severe renal impairment.
Dizziness and confusion are common enough to matter for driving, machinery, and risk-taking tasks.
Dizziness and headache are common adverse reactions in controlled trials and patient labeling.
Pregnancy and breastfeeding safety are unproven for unsupervised use.
Evidence uncertainty is high for healthy nootropic use despite regulated clinical evidence in a separate population.
These adverse effects appear in patient labeling and controlled-trial adverse-reaction summaries. They are especially important when considering driving, work, or combining CNS-active products.
Memantine is substantially cleared in urine. Labeling warns that A higher urine pH state that can slow renal elimination of some medicines.Source conditions can reduce clearance and increase exposure; examples include carbonic anhydrase inhibitors, sodium bicarbonate, renal tubular acidosis, and severe urinary-tract infections.
EU product information states that memantine can have a minor-to-moderate influence on the ability to drive and use machines. Dizziness and confusion make this relevant outside dementia care as well.
Interactions and cautions
Labeling says combined use with other NMDA antagonists has not been systematically evaluated and should be approached with caution.
Labeling gives sodium bicarbonate and carbonic anhydrase inhibitors as examples that can shift urine pH and reduce memantine clearance. Alkaline urine can also occur in renal tubular acidosis or severe urinary-tract infections.
Direct evidence for every combination is limited, but alcohol, sedatives, dissociatives, and other CNS-active products can make dizziness, confusion, sedation, and impairment harder to predict.
Legal and regulatory status
As checked on 2026-06-28, DailyMed/FDA labeling describes specific memantine hydrochloride tablet products as prescription medicines in an approved clinical context. This should not be written as a U.S. dietary supplement ingredient claim.
As checked on 2026-06-28, EMA pages list memantine hydrochloride products as medicines for moderate-to-severe Alzheimer's disease. Supply classification and brand/generic availability should be checked in the specific member state.
Practical buying and quality notes
- Because memantine is regulated as a prescription medicine in U.S. and EU sources checked on 2026-06-28, retail listings outside verified pharmacy channels should be treated as discovery signals only, not as endorsement of legality, suitability, pharmacy status, strength, or contaminant testing.1
- Most clinical labels use memantine hydrochloride. Strength statements may be expressed as hydrochloride salt or as base-equivalent memantine depending on product and jurisdiction, so labels should be read carefully.4
FAQ
Is memantine a supplement?
1No. In the U.S. and EU sources checked on 2026-06-28, memantine is presented as a prescription medicine, not a dietary supplement.
Does memantine improve memory in healthy people?
13Healthy nootropic evidence is unproven. The main evidence base is condition-specific, and the small healthy-volunteer evidence available here does not support broad cognitive-enhancement claims.
Why does urine pH matter for memantine?
1Memantine is substantially cleared through urine. Labeling warns that alkaline urine can reduce clearance and increase exposure, which can raise adverse-effect risk.
What are common memantine side effects?
2Label summaries list dizziness, headache, confusion, and constipation as common adverse reactions. Dizziness and confusion make driving, machinery, and CNS-active combinations important caution areas.
References
- DailyMed. Memantine hydrochloride tablets prescribing information.
- DailyMed. Memantine hydrochloride tablet patient information and adverse reactions.
- European Medicines Agency. Ebixa EPAR overview.
- European Medicines Agency. Ebixa EPAR product information.
- European Medicines Agency. Axura EPAR scientific discussion.
- U.S. Food and Drug Administration. Namenda (memantine hydrochloride) oral solution clinical pharmacology and biopharmaceutics review. NDA 21-627. 2005.
- NHS. Common questions about memantine.
- electronic Medicines Compendium. Memantine Mylan 10 mg film-coated tablets Summary of Product Characteristics.
- Liu MY, Meng SN, Wu HZ, Wang S, Wei MJ. Pharmacokinetics of single-dose and multiple-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clinical Therapeutics. 2008;30(4):641-653.
- McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019.
- PubChem Compound Summary for CID 4054, Memantine.
- PubChem Compound Summary for CID 181458, Memantine hydrochloride.
- Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Loeschmann PA. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neuroscience Letters. 1997;224(1):57-60.
- Johnson JW, Kotermanski SE. Mechanism of action of memantine. Current Opinion in Pharmacology. 2006;6(1):61-67.